LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭

doi:10.16352/j.issn.1001-6325.2023.07.1023

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (7): 1023-1029.doi: 10.16352/j.issn.1001-6325.2023.07.1023

• 研究论文 • 下一篇

LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭

唐一君¹, 王文龙^2,*, 李江丽¹, 杨欢³, 孙静¹

1.河南科技大学附属安阳市肿瘤医院肿瘤内科五病区, 河南安阳 455000;
2.河南科技大学附属安阳市肿瘤医院外科五病区, 河南安阳 455000;
3.苏州大学附属第一医院甲乳外科, 江苏苏州 215006

收稿日期:2022-07-07 修回日期:2022-11-13 出版日期:2023-07-05 发布日期:2023-07-05
通讯作者: ^*wwlnanyang@163.com
基金资助:
国家自然科学基金(81702078)

LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines

TANG Yijun¹, WANG Wenlong^2,*, LI Jiangli¹, YANG Huan³, SUN Jing¹

1. Department of the Fifth Ward of Medical Oncology, Anyang Cancer Hospital Affiliated to Henan University of Science and Technology, Anyang 455000;
2. Department of the Fifth Ward of Surgery, Anyang Cancer Hospital Affiliated to Henan University of Science and Technology, Anyang 455000;
3. Department of Thyroid and Breast Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China

Received:2022-07-07 Revised:2022-11-13 Online:2023-07-05 Published:2023-07-05

摘要/Abstract

摘要： 目的分析长链非编码RNA(lncRNA) RP11-686D22.10表达水平与乳腺癌患者生存期的关系,探讨过表达RP11-686D22.10对乳腺癌细胞系增殖和侵袭的影响及其分子机制。方法 GEPIA数据库分析RP11-686D22.10表达水平与乳腺癌患者生存期的关系。RT-qPCR检测乳腺上皮细胞系MCF-10A和乳腺癌细胞系MCF7、SKBR3、HCC1937、BT549和MB-MDA-468中RP11-686D22.10的表达量。选择RP11-686D22.10表达水平最低的SKBR3细胞,分别转染对照质粒(NC组)和RP11-686D22.10过表达质粒(RP11-686D22.10组)。CCK-8法和Transwell小室法分别检测乳腺癌细胞增殖及侵袭。Linc2Go数据库预测RP11-686D22.10的靶向微小RNA(miRNA),双荧光素酶报告基因实验检测RP11-686D22.10和miR-454-3p的靶向关系。RT-qPCR检测miR-454-3p表达量。Western blot检测Wnt/β-catenin信号通路蛋白质表达量。结果与RP11-686D22.10低表达乳腺癌患者相比,RP11-686D22.10高表达患者的总生存期较长(P<0.01),并且无病生存期较长(P<0.01)。MCF7、SKBR3、HCC1937、BT549和MB-MDA-468乳腺癌细胞中RP11-686D22.10表达量低于MCF-10A细胞(P<0.05),SKBR3细胞中RP11-686D22.10表达最低(P<0.01)。与NC组比较,RP11-686D22.10组SKBR3细胞增殖能力降低(P<0.05),并且细胞侵袭能力降低(P<0.01)。RP11-686D22.10能够靶向结合miR-454-3p(P<0.01)。与NC组比较,RP11-686D22.10组miR-454-3p表达量降低(P<0.01),Wnt/β-catenin信号通路蛋白CCND1、β-catenin、JUN、AXIN2和MMP2表达量降低。结论 RP11-686D22.10表达水平与乳腺癌患者生存期密切相关,过表达RP11-686D22.10通过靶向调控miR-454-3p抑制乳腺癌细胞系的增殖及侵袭。

关键词: 乳腺癌, RP11-686D22.10, miR-454-3p, 增殖, 侵袭

Abstract: Objective To dientify the correlation between the expression of long-chain non-coding RNA (lncRNA) RP11-686D22.10 and the survival of breast cancer patients, and to explore the effect of over-expression of RP11-686D22.10 on the proliferation and invasion of breast cancer cell lines. Methods The relationship between the expression level of RP11-686D22.10 and the survival time of breast cancer patients was analyzed with GEPIA database. The expression of RP11-686D22.10 in mammary epithelial cell line MCF-10A and breast cancer cell lines MCF7, SKBR3, HCC1937, BT549 and MB-MDA-468 was detected by real-time quantitative polymerase chain reaction (RT-qPCR). SKBR3 cell with the least expression of RP11-686D22.10 was selected and transfected with control plasmid (NC group) and RP11-686D22.10 over-expression plasmid (RP11-686D22.10 group). The proliferation and invasion of breast cancer cells were detected by CCK-8 and Transwell assays, respectively. The Linc2Go database predicted the targeting microRNA (miRNA) of RP11-686D22.10, and the dual-luciferase reporter gene assay was used to target at relationship between RP11-686D22.10 and miR-454-3p. The expression of miR-454-3p was detected by RT-qPCR. Western blot was used to detect the protein expression of Wnt/β-catenin signaling pathway. Results Compared with breast cancer patients with low expression of RP11-686D22.10, patients with high expression of RP11-686D22.10 had longer overall survival (P<0.01) and longer disease-free survival (P<0.01). The expression of RP11-686D22.10 in MCF7, SKBR3, HCC1937, BT549, and MB-MDA-468 cells was lower than that in MCF-10A cell (P<0.05). The expression of RP11-686D22.10 in SKBR3 cells was the lowest (P<0.01). Compared with the NC group, the proliferation ability of SKBR3 cells in the RP11-686D22.10 group was decreased (P<0.05), and the cell invasion ability was decreased (P<0.01). RP11-686D22.10 could target and bind miR-454-3p (P<0.01). Compared with the NC group, the expression of miR-454-3p in the RP11-686D22.10 group was decreased (P<0.01), and the expressions of Wnt/β-catenin signaling pathway proteins CCND1, β-catenin, JUN, AXIN2, and MMP2 was decreased. Conclusions The expression level of RP11-686D22.10 is closely related to the survival of breast cancer patients. Over-expression of RP11-686D22.10 inhibits the proliferation and invasion of breast cancer cell lines by targeting at miR-454-3p.

Key words: breast cancer, RP11-686D22.10, miR-454-3p, proliferation, invasion

中图分类号:

R737.14

唐一君, 王文龙, 李江丽, 杨欢, 孙静. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43(7): 1023-1029.

TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines[J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.07.1023

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I7/1023

参考文献

[1] Li X, Jin F, Li Y.A novel autophagy-related lncRNA prognostic risk model for breast cancer[J]. J Cell Mol Med, 2021, 25: 4-14.
[2] Pardini B, Dragomir MP.SCIRT lncRNA blocks the shot of breast cancer cells self-renewal mechanism[J]. Cancer Res, 2021, 81: 535-536.
[3] Li Y, Zhang M, Li F.LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN[J]. Histol Histopathol, 2020, 35: 1171-1180.
[4] Shen Y, Peng X, Shen C.Identification and validation of immune-related lncRNA prognostic signature for breast cancer[J]. Genomics, 2020, 112: 2640-2646.
[5] Zhao Z, Guo Y, Liu Y, et al. Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer[J]. Oncogene, 2021, 40: 4604-4614.
[6] Zhou J, Zhang S, Luo M.LncRNA PCAT7 promotes the malignant progression of breast cancer by regulating ErbB/PI3K/Akt pathway[J]. Future Oncol, 2021, 17: 701-710.
[7] Wu D, Zhu J, Fu Y, et al. LncRNA HOTAIR promotes breast cancer progression through regulating the miR-129-5p/FZD7 axis[J]. Cancer Biomark, 2021, 30: 203-212.
[8] Zhu L, Wang F, Fan W, et al. LncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis[J]. Acta Biochim Biophys Sin (Shanghai), 2021, 53: 1198-1206.
[9] Han L, Yan Y, Zhao L, et al. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/WNT1 pathway[J]. J Cell Mol Med, 2020, 24: 6242-6252.
[10] Zhang S, Wang B, Xiao H, et al. LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p[J]. Thorac Cancer, 2020, 11: 1801-1816.
[11] Ouyang J, Liu Z, Yuan X, et al. LncRNA PRNCR1 promotes breast cancer proliferation and inhibits apoptosis by modulating microRNA-377/CCND2/MEK/MAPK axis[J]. Arch Med Res, 2021, 52: 471-482.
[12] Zong S, Dai W, Guo X, et al. LncRNA-SNHG1 promotes macrophage M2-like polarization and contributes to breast cancer growth and metastasis[J]. Aging (Albany NY), 2021, 13: 23169-23181.
[13] Qian XL, Zhou F, Xu S, et al. miR-454-3p promotes oxaliplatin resistance by targeting PTEN in colorectal cancer[J]. Front Oncol, 2021, 11: 638537. doi: 10.3389/fonc.2021.638537.
[14] Shen G, Wu J, Mou Z, et al. miR-454-3p promotes of human glioma cell growth by targeting EGR3[J]. Exp Ther Med, 2019, 18: 4031-4039.
[15] Ren L, Chen H, Song J, et al. miR-454-3p-mediated Wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis[J]. Theranostics, 2019, 9: 449-465.

LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭

LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张培波, 李义. 沙棘总黄酮抑制膀胱癌细胞系T24增殖[J]. 基础医学与临床, 2023, 43(7): 1122-1126.
[2]	金晓霞, 陆晓云, 刘玉山, 梁李娜. SIRT2在膀胱尿路上皮癌中的表达、临床意义及其对癌细胞增殖、侵袭和迁移的影响[J]. 基础医学与临床, 2023, 43(7): 1090-1096.
[3]	曾燕坤, 洪小颖, 陈清林. 下调BECN1抑制人白血病细胞系THP-1增殖、侵袭和迁移[J]. 基础医学与临床, 2023, 43(7): 1104-1109.
[4]	苏靓誉, 张振西, 杜文静. TPX2的表达对胰腺癌预后的影响[J]. 基础医学与临床, 2023, 43(6): 875-881.
[5]	侯孟杰, 赵娜, 黄富强, 王亚南, 刘芳铭. 载脂蛋白E通过降低高尔基体膜蛋白73表达抑制小鼠肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(5): 762-770.
[6]	刘月, 曹阳, 顾伟英, 商丽梅, 刘琰. 地西他滨联合三氧化二砷抑制急性髓系白血病细胞系增殖和促进凋亡[J]. 基础医学与临床, 2023, 43(4): 608-614.
[7]	冷海娜, 张艳, 王晓栋, 张学友, 李洪利. miR-767-5p通过调控TBL1XR1蛋白表达抑制人卵巢癌细胞系侵袭[J]. 基础医学与临床, 2023, 43(3): 408-414.
[8]	王芳芳, 曹慧媛, 汪婧, 王宁, 黄国良. 上调miR-200c-5p的表达抑制人结直肠癌细胞系SW480增殖[J]. 基础医学与临床, 2023, 43(2): 241-245.
[9]	杨良权, 于淼, 姜茜, 张明慧, 杨海松. miR-504调控蛋白酶体激活因子抑制人乳腺癌细胞系MCF-7增殖及迁移[J]. 基础医学与临床, 2023, 43(1): 95-101.
[10]	王群, 李鑫, 马俊, 李婉明. 核酸适配体W3介导靶向乳腺癌的量子点成像[J]. 基础医学与临床, 2023, 43(1): 76-82.
[11]	贺晶, 李艳, 王延峰, 鲍慧. FABP4表达上调促进人子宫内膜癌细胞系HEC-1-A增殖和迁移[J]. 基础医学与临床, 2022, 42(9): 1356-1361.
[12]	张晓雷, 刘静, 李朝萍. Circ_0032821参与索拉非尼抑制乳腺癌细胞系T47D增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(9): 1350-1354.
[13]	王娟, 张晓燕, 朱爱华, 于宏波, 范新丹, 汤春辉, 姚秀芳. Ku70高表达促进人卵巢癌细胞系的增值并与卵巢癌患者不良预后相关[J]. 基础医学与临床, 2022, 42(9): 1391-1399.
[14]	沈永华, 汪峻峰, 程泽星, 冯娟娟. 秦皮甲素抑制人鼻咽癌细胞系HNE-3增殖[J]. 基础医学与临床, 2022, 42(8): 1237-1242.
[15]	谢思安, 陈奕阳, 徐俊玄, 宁婷婷, 张楠, 朱圣韬, 张澍田. PTOV1表达水平对结直肠癌患者预后的影响[J]. 基础医学与临床, 2022, 42(8): 1176-1181.